AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00959868
Drug: OGX-427
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OGX-427 drug product is in 25mg/mL injection in a mannitol-phosphate buffer solution packaged to deliver at least 8mL volume from a 10mL Type I, clear glass vial (ammonium sulfate treated) with Teflon coated bromobutyl rubber stopper and sealed with an aluminum, red, flip-off over seal. The drug product is aseptically compounded and sterilized via sterile filtration prior to aseptic filling.
Trial: NCT01399788
Drug: Myrin P Forte
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, given once daily, single dose
Trial: NCT01399788
Drug: Single drug references
FDA approved: no
EMA approved: no
PMDA approved: no
Description: containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide as single agents
Trial: NCT01500278
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Active substance: Methotrexate~* Pharmaceutical form: oral tablet~* Concentration: 15-25 mg/week~* Route of Administration: MTX orally
Trial: NCT01698164
Drug: estradiol plus MPA
RxNorm normalized name: polyurethane-34 (55 MPA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are given estradiol and synthetic progestin.
Trial: NCT01698164
Drug: estradiol plus progesterone
RxNorm normalized name: ESTRADIOL/PROGESTERONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are given estradiol and natural progesterone.
Trial: NCT01285115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
Trial: NCT01285115
Drug: KyungBangn-Gamisoyosan-x-gwarip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
Trial: NCT02818543
Drug: LYC-30937
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01285115
Drug: KyungBangn Gamisoyosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
Trial: NCT03024515
Drug: opioids titration
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Practice Arm
Trial: NCT00351676
Drug: Optimizing therapeutic treatments
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01581658
Drug: BI10773
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI10773 medium dose tablet single dose
Trial: NCT01421277
Drug: Statin Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice of any statin.
Trial: NCT04975035
Drug: Zolodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collect 200 patients who meet the criteria into the group. After enrollment, according to the principle of cross dressing change, the attending physician can decide the dressing change method according to the patient's condition, individual condition and other factors; within 2-4 weeks, the original antipsychotics should be gradually stopped, and Zoladine capsules will be gradually added to the target The dose is 120-160mg/d, orally 1-2 times a day, with meals.
Trial: NCT03682653
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a single dose of Azithromycin will be administered to infants between their 8-27th days of life
Trial: NCT03682653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of Placebo will be administered to infants between their 8-27th days of life
Trial: NCT00002788
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04198363
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin Tablets
Trial: NCT04342650
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg placebo tablets
Trial: NCT03649477
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three times per day with meals
Trial: NCT01597245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02919878
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is given post operatively as adjuvant chemotherapy for 6 cycles. Each cycle consist of 2500 mg/m2 per day given orally from D1-14
Trial: NCT04187352
Drug: CS1001+ Fluorouracil+Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CS1001 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle.
Trial: NCT04187352
Drug: Placebo+ Fluorouracil+Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle.
Trial: NCT03282916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sugar pill 500mg caplet
Trial: NCT00482430
Drug: MK0557
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0557 10mg tablet qd for a 15-wk treatment period
Trial: NCT00482430
Drug: Comparator: Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0557 Pbo tablet qd for a 15-wk treatment period
Trial: NCT02529787
Drug: Doxirazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule contains 60 mg Dexlansoprazole
Trial: NCT00859430
Drug: Keppra®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Tablet
Trial: NCT01576549
Drug: LY2127399
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT00999232
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receive 4x250mg erythromycin i.v. daily after intubation of a self-propelled feeding tube
Trial: NCT00999232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive 4x placebo i.v. daily after intubation of a self-propelled feeding tube
Trial: NCT00003715
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003715
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00722124
Drug: S-Adenosyl-L-Methionine
RxNorm normalized name: S-Adenosyl-L-Methionine (Sam-E)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg dose per day for 8 weeks
Trial: NCT00722124
Drug: S-Adenosyl-L-Methionine
RxNorm normalized name: S-Adenosyl-L-Methionine (Sam-E)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mg per day for 8 weeks
Trial: NCT03294785
Drug: Conventional medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
Trial: NCT03421834
Drug: Optimal medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal guidelines-based heart failure treatment and antiarrhythmic drugs. Antiarrhythmics will be avoided if possible in the ablation group.
Trial: NCT00730938
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml of Ringers lactate
Trial: NCT01294787
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00097344
Drug: Aromatase inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00097344
Drug: Estrogen receptor blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01830504
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM 120, 100 mg/day continuously. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow the patient to continue the study treatment. Dose level -1 : 80 mg/day continuously, Dose level -2 : 80 mg/day 5 days out of 7. All dose modifications, interruptions or discontinuations must be based on the worst preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03.~A change from continuous schedule to intermittent (5 days out of 7) must be preceded by 2 days without treatment.
Trial: NCT00027053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02071303
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200mg will be given to 70 women before the procedure.
Trial: NCT02071303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo will be given to 70 women before the procedure.
Trial: NCT01725529
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435 100 mg or 150 mg capsules taken orally (by mouth) with food once-daily for 12 weeks (Week 12).
Trial: NCT01725529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules taken orally with food once-daily for 48 weeks.
Trial: NCT00133991
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1500 mg/m\^2 on Day 1 of each R-CVP cycle. 50 mg/kg/day on Days -3, -2, -1, and 0 of HiCy.
Trial: NCT00133991
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 g/m\^2 on Day 8 of each cycle of R-CVP.
Trial: NCT02997202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01199133
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One sublingual tablet daily for one year.
Trial: NCT00133991
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
Trial: NCT00133991
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mg four times daily after methotrexate administration. Dosing continues until adequate methotrexate levels are reached.
Trial: NCT00634309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02334449
Drug: LML134
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LML134 will be administered first as single doses and then as multiple doses
Trial: NCT02334449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All study cohorts (except food effect cohort) are placebo controlled
Trial: NCT01686451
Drug: XueZhiKang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
Trial: NCT01686451
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 20mg of simvastatin daily for 4 weeks.
Trial: NCT01452815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two #2 oval shaped,opaque-white, hard gelatin shell capsules containing inactive ingredients taken orally once daily for 12 weeks.
Trial: NCT01107093
Drug: CDB-2914 (ulipristal acetate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of 30 mg
Trial: NCT01107093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT01669070
Drug: FF, 50 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel dry powder inhaler
Trial: NCT01669070
Drug: FF, 100 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel dry powder inhaler
Trial: NCT00079625
Drug: Th2/Tc2 Cells
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01310647
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (20µg/kg/day)from day 24 of the previous cycle to day 2 of the ICSI cycle
Trial: NCT01669070
Drug: FF, 200 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel dry powder inhaler
Trial: NCT01669070
Drug: FF, 250 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT01310647
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle
Trial: NCT01310647
Drug: CombEq
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI.~Valerate estradiol 4mg/day during 10 days, starting the second day of the cycle prios to the ICSI cycle.
Trial: NCT02055963
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
Trial: NCT02055963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
Trial: NCT00547846
Drug: PDC-748
RxNorm normalized name: chlorpheniramine maleate / dihydrocodeine bitartrate / phenylephrine hydrochloride Oral Solution [Despec-PDC]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03491072
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive IV fentanyl
Trial: NCT00267670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill PO TID
Trial: NCT00785629
Drug: Calcium acetate
RxNorm normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02821507
Drug: sirolimus and cyclophosphamide
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00785629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04408079
Drug: TQB3558
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3558 is a kinase inhibitor of the TRK protein family.
Trial: NCT02339207
Drug: AL-335 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01880931
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The effect site concentration of remifentanil
Trial: NCT02517684
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00225030
Drug: antihypertensive drugs according to current guidelines
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02648906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02517684
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00946374
Drug: Immunochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP: Rituximab 375 mg/m²,intravenous ( iv ), day 0 ; Cyclophosphamide 750 mg/m²,iv, day1; Vincristine 1,4 mg/m² but at the maximum 2 mg,iv,d1; Doxorubicin 50 mg/m², iv, d1; Prednisone 100 mg, peroral ( po ), day 1 to day 5
Trial: NCT00946374
Drug: High-dose BEAM plus autologous SCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose BEAM: Carmustine 300mg/m², iv, day -7; Cytarabine 2 x 200 mg/m², iv, day -6 to day -3; Etoposide 2 x 100 mg/m², iv, day -6 to day -3; Melphalan 140 mg/m², iv, day -2 followed by Autologous stem cell transplantation ( \> 2,5 x 10e6 CD34 positive autologous stem cells, iv, day 0
Trial: NCT00935480
Drug: Isentress®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P.O, 1 tablet containing 400 mg every 12 hours
Trial: NCT00935480
Drug: Celsentri®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)
Trial: NCT02290873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive control arm
Trial: NCT04089735
Drug: APP13007 Placebo, 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APP13007 placebo eyedrop, 0.1%
Trial: NCT01108029
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of placebo 1 time a day in the morning
Trial: NCT01230541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily, oral tablet
Trial: NCT00577642
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4mg IV over at least 15 minutes or corrected for creatinine clearance x 1
Trial: NCT01755078
Drug: Calcium-based phosphate binder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01747642
Drug: Suranix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
Trial: NCT02595476
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00725569
Drug: Bellis perennis and Staphysagria (C6)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: homeopathic remedy
Trial: NCT00725569
Drug: Bellis perennis and Staphysagria (C30)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic Remedy
Trial: NCT00725569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo remedy, identical in size, shape and taste to treatment remedies
Trial: NCT01443520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be given orally placebo twice a day for 8 days prior to the study.
Trial: NCT00736255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects on this arm will receive matching placebo, along with Nicotine Replacement Therapy.
Trial: NCT01841944
Drug: Pikasol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
Trial: NCT01183143
Drug: GONAL-f®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.
Trial: NCT03370783
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate alcohol consumption
Trial: NCT00239798
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04135235
Drug: TAF
RxNorm normalized name: Altafed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol tenofovir fumarate
Trial: NCT01530880
Drug: Intravenous Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400 mg/100 mL intravenous (IV) over 30 minutes, followed by a continuous infusion of 2000 mg/500 mL at 85 mg/hour (21 mL/hour) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first
Trial: NCT01530880
Drug: Acetaminophen (Standard of Care)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg via oral/nasogastric tube every 6 hours as needed for T\>=38.3 C (100.9 F) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first.
Trial: NCT01424124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, one times daily / 7 days
Trial: NCT02241759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00762060
Drug: Patient controlled analgesia
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV opioids delivered via PCA
Trial: NCT02531581
Drug: NaCl 9% isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline 500 cc / 4 hours and 1 L / 24 hours
Trial: NCT01601028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2cp/day for 12 weeks and go off medication for 4 weeks (total 16 weeks)
Trial: NCT01338831
Drug: LFA102
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01627158
Drug: Symbicort Turbuhaler
RxNorm normalized name: Symbicort Turbuhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort Turbuhaler